"Pyridazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
Descriptor ID |
D011724
|
MeSH Number(s) |
D03.383.710
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridazines".
Below are MeSH descriptors whose meaning is more specific than "Pyridazines".
This graph shows the total number of publications written about "Pyridazines" by people in this website by year, and whether "Pyridazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 1 | 0 | 1 |
2007 | 1 | 1 | 2 |
2009 | 2 | 0 | 2 |
2010 | 2 | 0 | 2 |
2011 | 4 | 3 | 7 |
2012 | 4 | 3 | 7 |
2013 | 7 | 4 | 11 |
2014 | 7 | 3 | 10 |
2015 | 12 | 5 | 17 |
2016 | 4 | 3 | 7 |
2017 | 4 | 2 | 6 |
2018 | 6 | 2 | 8 |
2019 | 4 | 2 | 6 |
2020 | 2 | 4 | 6 |
2021 | 7 | 0 | 7 |
2022 | 8 | 3 | 11 |
2023 | 2 | 0 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridazines" by people in Profiles.
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
-
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.
-
Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leuk Lymphoma. 2023 01; 64(1):79-86.
-
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol. 2022 10 03; 24(10):1712-1725.
-
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 11; 97(11):1419-1426.
-
Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022 Sep; 97(9):E350-E352.
-
DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Mol Cancer Res. 2022 07 06; 20(7):1137-1150.
-
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother. 2022 May; 23(7):751-758.
-
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clin Cancer Res. 2022 04 01; 28(7):1268-1276.